Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 99.83
ICAD's Cash-to-Debt is ranked higher than
59% of the 1921 Companies
in the Global Software - Application industry.

( Industry Median: 10.13 vs. ICAD: 99.83 )
Ranked among companies with meaningful Cash-to-Debt only.
ICAD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.73 Max: No Debt
Current: 99.83
Equity-to-Asset 0.65
ICAD's Equity-to-Asset is ranked higher than
58% of the 1830 Companies
in the Global Software - Application industry.

( Industry Median: 0.60 vs. ICAD: 0.65 )
Ranked among companies with meaningful Equity-to-Asset only.
ICAD' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.39  Med: 0.65 Max: 0.91
Current: 0.65
-0.39
0.91
Piotroski F-Score: 4
Altman Z-Score: -3.32
Beneish M-Score: -3.31
WACC vs ROIC
10.56%
-56.68%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -37.85
ICAD's Operating Margin % is ranked lower than
87% of the 1862 Companies
in the Global Software - Application industry.

( Industry Median: 4.84 vs. ICAD: -37.85 )
Ranked among companies with meaningful Operating Margin % only.
ICAD' s Operating Margin % Range Over the Past 10 Years
Min: -129.54  Med: -13.35 Max: 12.71
Current: -37.85
-129.54
12.71
Net Margin % -38.34
ICAD's Net Margin % is ranked lower than
85% of the 1863 Companies
in the Global Software - Application industry.

( Industry Median: 3.19 vs. ICAD: -38.34 )
Ranked among companies with meaningful Net Margin % only.
ICAD' s Net Margin % Range Over the Past 10 Years
Min: -131.18  Med: -24.17 Max: 11.62
Current: -38.34
-131.18
11.62
ROE % -34.55
ICAD's ROE % is ranked lower than
85% of the 1803 Companies
in the Global Software - Application industry.

( Industry Median: 6.16 vs. ICAD: -34.55 )
Ranked among companies with meaningful ROE % only.
ICAD' s ROE % Range Over the Past 10 Years
Min: -68.8  Med: -19.17 Max: 7.57
Current: -34.55
-68.8
7.57
ROA % -23.18
ICAD's ROA % is ranked lower than
83% of the 1927 Companies
in the Global Software - Application industry.

( Industry Median: 2.92 vs. ICAD: -23.18 )
Ranked among companies with meaningful ROA % only.
ICAD' s ROA % Range Over the Past 10 Years
Min: -51.56  Med: -10.12 Max: 6.46
Current: -23.18
-51.56
6.46
ROC (Joel Greenblatt) % -531.22
ICAD's ROC (Joel Greenblatt) % is ranked lower than
88% of the 1883 Companies
in the Global Software - Application industry.

( Industry Median: 23.13 vs. ICAD: -531.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ICAD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1592.49  Med: -300.91 Max: 178.33
Current: -531.22
-1592.49
178.33
3-Year Revenue Growth Rate -18.50
ICAD's 3-Year Revenue Growth Rate is ranked lower than
87% of the 1454 Companies
in the Global Software - Application industry.

( Industry Median: 5.30 vs. ICAD: -18.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ICAD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -41.4  Med: -4.3 Max: 78.4
Current: -18.5
-41.4
78.4
3-Year EBITDA Growth Rate 43.00
ICAD's 3-Year EBITDA Growth Rate is ranked higher than
87% of the 1210 Companies
in the Global Software - Application industry.

( Industry Median: 8.40 vs. ICAD: 43.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ICAD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -76  Med: -16.45 Max: 217.8
Current: 43
-76
217.8
3-Year EPS without NRI Growth Rate -3.50
ICAD's 3-Year EPS without NRI Growth Rate is ranked lower than
64% of the 1098 Companies
in the Global Software - Application industry.

( Industry Median: 7.70 vs. ICAD: -3.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ICAD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -72.7  Med: -8.7 Max: 96.6
Current: -3.5
-72.7
96.6
GuruFocus has detected 3 Warning Signs with icad Inc $ICAD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ICAD's 10-Y Financials

Financials (Next Earnings Date: 2017-06-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ICAD Guru Trades in Q1 2016

Jim Simons 430,360 sh (+2.20%)
» More
Q2 2016

ICAD Guru Trades in Q2 2016

Jim Simons 459,360 sh (+6.74%)
» More
Q3 2016

ICAD Guru Trades in Q3 2016

Jim Simons 491,960 sh (+7.10%)
» More
Q4 2016

ICAD Guru Trades in Q4 2016

Jim Simons 517,560 sh (+5.20%)
» More
» Details

Insider Trades

Latest Guru Trades with ICAD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Application Software » Software - Application    NAICS: 333316    SIC: 3841
Compare:NAS:SEAC, AMEX:GSB, NAS:ASUR, NAS:COVS, NYSE:STV, NAS:ARIS, OTCPK:MSRT, OTCPK:IWSY, OTCPK:SCSYF, OTCPK:RWWI, NYSE:TRMR, NAS:DWCH, NYSE:MRIN, OTCPK:MONIF, NAS:AWRE, OTCPK:CATDF, NAS:BSQR, AMEX:GVP, NAS:APPS, NAS:EVOL » details
Traded in other countries:HWT1.Germany,
Headquarter Location:USA
icad Inc is a provider of image analysis, work flow solutions and radiation therapy for early identification and treatment of cancer. The company has cancer detection and cancer therapy segments.

icad Inc was incorporated in the State of Delaware on February 24, 1984. The Company is a provider of image analysis and workflow solutions that enable radiologists and other healthcare professionals to serve patients by identifying pathologies and pinpointing cancer earlier. It high-performance, expandable Computer-Aided Detection (CAD) systems and workflow solutions for mammography, such as film-based, digital radiography (DR), in addition to computed radiography (CR), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). It offers a comprehensive range of high-performance upgradeable products for use with mammography, including digital radiography, computed radiography and film-based mammography. These solutions enable radiologists to serve patients by identifying pathologies and pinpointing cancers. The company's solutions aid in the early detection of the prevalent cancers including breast, prostate and colon cancer. Early detection of cancer is the key to prognosis, less invasive and lower treatment costs, and higher survival rates. The company's products are manufactured and assembled for it by a contract manufacturer of medical devices. Its manufacturing efforts are generally limited to purchasing and supply chain management, planning/scheduling, manufacturing engineering, service repairs, quality assurance, inventory management, and warehousing. Its products are sold through its direct regional sales organization in the U.S. as well as through its OEM partners, including GE Healthcare, Fuji Medical Systems, Siemens Medical, Philips Healthcare, Agfa Corporation, Sectra Medical Systems, Planmed, Fuji Medical Systems, IMS Giotto, and Carestream. The Company currently faces direct competition in its CAD business from Hologic, Inc. and imaging equipment manufacturers such as GE Healthcare, Siemens Medical, and Philips Medical Systems. The Company's systems are medical devices subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act with potentially costs for compliance.

Top Ranked Articles about icad Inc

iCAD to Report First Quarter 2017 Financial Results on Tuesday, May 2
iCAD to Present at the 29th Annual ROTH Conference

NASHUA, N.H., March 02, 2017 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will present at the 29th Annual ROTH Conference in Dana Point, CA. Ken Ferry, Chief Executive Officer, and Rich Christopher, Executive Vice President and Chief Financial Officer, will be presenting, as well as meeting with investors.   Event:29th Annual ROTH ConferenceDate:Wednesday, March 15, 2017Time:9:30 am PT / 12:30 pm ET   An audio webcast of the Company’s presentation will be available online at www.icadmed.com. A replay of the presentations will be available for 90 days.
About iCAD, Inc. iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit or www.icadmed.com or www.xoftinc.com. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995 Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
Contact:
For iCAD investor relations:
The Ruth Group
Zack Kubow, 646-536-7020
[email protected]

or

For iCAD media inquiries:
Berry & Company Public Relations, LLC
Jessica Burns, 212-253-8881
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 3.56
ICAD's PB Ratio is ranked lower than
51% of the 1789 Companies
in the Global Software - Application industry.

( Industry Median: 2.97 vs. ICAD: 3.56 )
Ranked among companies with meaningful PB Ratio only.
ICAD' s PB Ratio Range Over the Past 10 Years
Min: 0.43  Med: 1.81 Max: 6.59
Current: 3.56
0.43
6.59
PS Ratio 3.39
ICAD's PS Ratio is ranked lower than
57% of the 1780 Companies
in the Global Software - Application industry.

( Industry Median: 2.34 vs. ICAD: 3.39 )
Ranked among companies with meaningful PS Ratio only.
ICAD' s PS Ratio Range Over the Past 10 Years
Min: 0.77  Med: 2.45 Max: 9.26
Current: 3.39
0.77
9.26
EV-to-EBIT -7.35
ICAD's EV-to-EBIT is ranked lower than
99.99% of the 1770 Companies
in the Global Software - Application industry.

( Industry Median: 17.68 vs. ICAD: -7.35 )
Ranked among companies with meaningful EV-to-EBIT only.
ICAD' s EV-to-EBIT Range Over the Past 10 Years
Min: -894.4  Med: -8.7 Max: 394.1
Current: -7.35
-894.4
394.1
EV-to-EBITDA -9.52
ICAD's EV-to-EBITDA is ranked lower than
99.99% of the 1910 Companies
in the Global Software - Application industry.

( Industry Median: 13.76 vs. ICAD: -9.52 )
Ranked among companies with meaningful EV-to-EBITDA only.
ICAD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2491.9  Med: -6.9 Max: 1529.5
Current: -9.52
-2491.9
1529.5
Current Ratio 1.55
ICAD's Current Ratio is ranked lower than
62% of the 1750 Companies
in the Global Software - Application industry.

( Industry Median: 1.94 vs. ICAD: 1.55 )
Ranked among companies with meaningful Current Ratio only.
ICAD' s Current Ratio Range Over the Past 10 Years
Min: 0.72  Med: 2.22 Max: 6.15
Current: 1.55
0.72
6.15
Quick Ratio 1.26
ICAD's Quick Ratio is ranked lower than
69% of the 1750 Companies
in the Global Software - Application industry.

( Industry Median: 1.79 vs. ICAD: 1.26 )
Ranked among companies with meaningful Quick Ratio only.
ICAD' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.32 Max: 3.18
Current: 1.26
0.61
3.18
Days Inventory 200.41
ICAD's Days Inventory is ranked lower than
94% of the 1086 Companies
in the Global Software - Application industry.

( Industry Median: 18.20 vs. ICAD: 200.41 )
Ranked among companies with meaningful Days Inventory only.
ICAD' s Days Inventory Range Over the Past 10 Years
Min: 59  Med: 99.01 Max: 200.41
Current: 200.41
59
200.41
Days Sales Outstanding 71.91
ICAD's Days Sales Outstanding is ranked lower than
52% of the 1492 Companies
in the Global Software - Application industry.

( Industry Median: 68.98 vs. ICAD: 71.91 )
Ranked among companies with meaningful Days Sales Outstanding only.
ICAD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.34  Med: 65.03 Max: 88.93
Current: 71.91
50.34
88.93
Days Payable 73.61
ICAD's Days Payable is ranked higher than
69% of the 1330 Companies
in the Global Software - Application industry.

( Industry Median: 43.37 vs. ICAD: 73.61 )
Ranked among companies with meaningful Days Payable only.
ICAD' s Days Payable Range Over the Past 10 Years
Min: 47.64  Med: 108.57 Max: 186.91
Current: 73.61
47.64
186.91

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.80
ICAD's 3-Year Average Share Buyback Ratio is ranked lower than
81% of the 1148 Companies
in the Global Software - Application industry.

( Industry Median: -2.60 vs. ICAD: -13.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ICAD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -35.6  Med: -7.4 Max: -0.1
Current: -13.8
-35.6
-0.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 14.33
ICAD's Price-to-Net-Current-Asset-Value is ranked lower than
68% of the 1066 Companies
in the Global Software - Application industry.

( Industry Median: 7.31 vs. ICAD: 14.33 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ICAD' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.5  Med: 13.2 Max: 1010
Current: 14.33
3.5
1010
Price-to-Tangible-Book 11.65
ICAD's Price-to-Tangible-Book is ranked lower than
74% of the 1488 Companies
in the Global Software - Application industry.

( Industry Median: 4.38 vs. ICAD: 11.65 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ICAD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.66  Med: 6.57 Max: 273.15
Current: 11.65
2.66
273.15
Price-to-Median-PS-Value 1.38
ICAD's Price-to-Median-PS-Value is ranked lower than
53% of the 1498 Companies
in the Global Software - Application industry.

( Industry Median: 1.15 vs. ICAD: 1.38 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ICAD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.44  Med: 1.03 Max: 8.8
Current: 1.38
0.44
8.8
Earnings Yield (Greenblatt) % -13.67
ICAD's Earnings Yield (Greenblatt) % is ranked lower than
88% of the 2521 Companies
in the Global Software - Application industry.

( Industry Median: 3.23 vs. ICAD: -13.67 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ICAD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -14.33  Med: 2.3 Max: 19.2
Current: -13.67
-14.33
19.2

More Statistics

Revenue (TTM) (Mil) $26.34
EPS (TTM) $ -0.63
Beta1.39
Short Percentage of Float0.51%
52-Week Range $2.82 - 6.49
Shares Outstanding (Mil)16.16
» More Articles for ICAD

Headlines

Articles On GuruFocus.com
iCAD to Showcase Breakthrough Early-Stage Breast Cancer Treatment Utilizing the Xoft System at Ameri Apr 26 2017 
iCAD to Report First Quarter 2017 Financial Results on Tuesday, May 2 Apr 24 2017 
Researchers to Present Updated Clinical Data on Intraoperative Radiation Therapy Using the Xoft Syst Apr 20 2017 
iCAD To Showcase PowerLook Tomo Detection Technology At SBI/ACR Breast Imaging Symposium Apr 06 2017 
iCAD to Present at the 29th Annual ROTH Conference Mar 02 2017 
Icade: Post Stabilisation Notice Oct 05 2015 
Icade: Pre Stabilisation Notice Sep 02 2015 
Weekly CFO Buys Highlight: MCP, ICAD, BODY, VVTV, MCRI Sep 03 2012 
Weekly CFO Buys Highlight: BWEN, SGGH, ICAD, CMLS, MCP Aug 27 2012 
icad inc. Reports Operating Results (10-Q) Nov 09 2010 

More From Other Websites
iCAD to Showcase Breakthrough Early-Stage Breast Cancer Treatment Utilizing the Xoft System at... Apr 26 2017
iCAD to Report First Quarter 2017 Financial Results on Tuesday, May 2 Apr 24 2017
Researchers to Present Updated Clinical Data on Intraoperative Radiation Therapy Using the Xoft... Apr 20 2017
ICAD: Tomo FDA Approval Sets Stage For Next Growth Phase Apr 11 2017
iCAD To Showcase PowerLook Tomo Detection Technology At SBI/ACR Breast Imaging Symposium Apr 06 2017
ETFs with exposure to iCAD, Inc. : April 5, 2017 Apr 05 2017
iCAD, Inc. :ICAD-US: Earnings Analysis: Q4, 2016 By the Numbers : March 30, 2017 Mar 30 2017
iCAD Cancer Detecting Product Gets FDA Premarket OK Mar 27 2017
iCAD Receives FDA Approval For PowerLook Tomo Detection Mar 27 2017
ICAD: NMSC Utilization Revenue Ramp Taking Longer Mar 14 2017
iCAD Announces More Than 3,000 Early-Stage Breast Cancer Patients Treated with Intraoperative... Mar 09 2017
iCAD Reports Fourth Quarter and Full Year 2016 Financial Results Mar 08 2017
iCAD Showcases Targeted, Non-Surgical Non-Melanoma Skin Cancer Treatment at AAD 2017 Mar 03 2017
iCAD to Present at the 29th Annual ROTH Conference Mar 02 2017
iCAD to Host Fourth Quarter and Full Year 2016 Financial Results Conference Call on Wednesday, March... Feb 27 2017
ICAD: Certain Catalysts Expected to Return ICAD to Positive Revenue Growth in 2017 Feb 08 2017
iCAD to Present at the 9th Annual LD Micro Main Event Nov 30 2016
iCAD to Showcase Use of Artificial Intelligence in Medical Imaging at RSNA 2016 Nov 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)